Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond

Mittal, Kriti; Ebos, John M.L.; Rini, Brian I.

doi:10.1053/j.seminoncol.2014.02.007

Cited by 131 publications

(105 citation statements)

References 189 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…However, based on emerging evidence, an increase in the tumor vasculature does not definitively result in expected faster tumor growth, suggesting that endothelial cells of blood vessels may exert other functions in the tumor mass [18,19]. In the present study, Nogo-B was differentially expressed in the tumor vasculature, and endothelial Nogo-B silencing promoted endothelial cell proliferation but suppressed tumor growth via a paracrine TGFβ/Smad signaling, suggesting an extremely complex interplay between tumor blood vessels and tumor cells.…”

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Endothelial Nogo-B suppresses cancer cell proliferation via a paracrine TGF-β/Smad signaling

Li¹,

Cheng²,

Huang³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

WITHDRAWN: Endothelial Nogo-B suppresses cancer cell proliferation via a paracrine TGF-β/Smad signaling

Li¹,

Cheng²,

Huang³

et al. 2018

Oncotarget

View full text Add to dashboard Cite

show abstract

“…SS scrambled siRNA, PS PROX1 siRNA, FN fibronectin; Col I collagen I, Col IV collagen IV, MMP matrix metalloproteinase; ZO zonula occludens Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell… 111 apoptosis and by promoting the proliferation of human gastric cancer cells. Tumor angiogenesis and lymphangiogenesis are the key features of tumor progression and metastasis in various human cancers, including gastric cancer [20][21][22][23][24]. We assessed the impact of PROX1 expression on angiogenesisand lymphangiogenesis-promoting phenotypes of human gastric cancer cells by performing in vitro assays.…”

Section: Discussionmentioning

confidence: 99%

Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis

et al. 2016

View full text Add to dashboard Cite

Background Prospero homeobox 1 (PROX1) functions as a tumor suppressor gene or an oncogene in various cancer types. However, the distinct function of PROX1 in gastric cancer is unclear. We determined whether PROX1 affected the oncogenic behavior of gastric cancer cells and investigated its prognostic value in patients with gastric cancer. Methods A small interfering RNA against PROX1 was used to silence PROX1 expression in gastric cancer cell lines AGS and SNU638. Expression of PROX1 in gastric cancer tissues was investigated by performing immunohistochemistry. Apoptosis, proliferation, angiogenesis, and lymphangiogenesis were determined by performing the TUNEL assay and immunohistochemical staining for Ki-67, CD34, and D2-40. Results PROX1 knockdown induced apoptosis by activating cleaved caspase-3, caspase-7, caspase-9, and poly(ADP-ribose) polymerase, and by decreasing the expression of anti-apoptotic proteins Bcl-2 and Bcl-xL. PROX1 knockdown also suppressed tumor cell proliferation. In addition, PROX1 knockdown decreased lymphatic endothelial cell invasion and tube formation and the expression of vascular endothelial growth factor (VEGF)-C and -D and cyclooxygenase (COX)-2. However, PROX1 knockdown only decreased umbilical vein endothelial cell invasion, not tube formation. The mean Ki-67 labeling index and lymphatic vessel density value of PROX1-positive tumors were significantly higher than those of PROX1-negative tumors. However, no significant difference was observed between PROX1 expression and apoptotic index or microvessel density. PROX1 expression was significantly associated with age, cell differentiation, lymph node metastasis, cancer stage, and poor survival. Conclusions These results indicate that PROX1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis.

show abstract

“…Endostatin is currently considered one of the most effective endogenous vascular growth inhibitors. Research has shown that endostatin was associated with the onset and progression of leukemia (Mittal et al, 2014). Changes in serum endostatin and FGF-19 in patients with acute myeloid leukemia may affect chemotherapeutic sensitivity and prognosis; however, few studies have examined this.…”

Section: Discussionmentioning

confidence: 99%

Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Su¹,

Wang²,

Zhou³

et al. 2015

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. The present study aimed to explore the changes in serum endostatin and fibroblast growth factor 19 (FGF-19) in acute myeloid leukemia patients, and to determine their effects on chemotherapeutic sensitivity. Sixty acute myeloid leukemia patients and 30 healthy controls were included in the study. Patient serum endostatin and FGF-19 levels were measured on admission, and then, standard chemotherapy was administered. The patients were divided into 2 groups according to chemotherapeutic effects: 21 patients in the chemotherapeutic sensitivity group (complete remission + partial remission) and 39 in the chemotherapeutic resistance group (no remission + degradation). A receiver operating characteristic (ROC) curve was used to analyze the relationship of serum endostatin and FGF-19 levels with chemotherapeutic sensitivity in acute myeloid leukemia patients. The levels of serum endostatin and FGF-19 in acute myeloid leukemia patients before chemotherapy were significantly higher than those in the control group. Moreover, these levels significantly decreased after chemotherapy (P < 0.01). The levels of serum endostatin and FGF-19 in the chemotherapeutic sensitivity group were lower than those in the chemotherapeutic resistance group, both before and after chemotherapy (P < 0.05 and P < 0.01, respectively). ROC curve analysis showed that the predictive values of endostatin and FGF-19 were good, and there was no significant difference between these results. In conclusion, serum endostatin and FGF-19 can be used as predictors of chemotherapeutic sensitivity for acute myeloid leukemia patients, and may be important for determining prognosis.

show abstract

Angiogenesis and the Tumor Microenvironment: Vascular Endothelial Growth Factor and Beyond

Cited by 131 publications

References 189 publications

WITHDRAWN: Endothelial Nogo-B suppresses cancer cell proliferation via a paracrine TGF-β/Smad signaling

WITHDRAWN: Endothelial Nogo-B suppresses cancer cell proliferation via a paracrine TGF-β/Smad signaling

Prospero homeobox 1 mediates the progression of gastric cancer by inducing tumor cell proliferation and lymphangiogenesis

Effects of changes in serum endostatin and fibroblast growth factor 19 on the chemotherapeutic sensitivity in acute myeloid leukemia patients

Contact Info

Product

Resources

About